Frontline defense against the next pandemic: Antivirals for avian flu

Indian Journal of Pharmacology

Volumn 38, Issue 6, 2006, Pages 383-389

  Khan, Sohil A ^a   Rao, Padma G M ^a   Kumar, P ^b   Rodrigues, G ^b  

^a MANIPAL COLLEGE OF PHARMACEUTICAL SCIENCES   (India)

^b KASTURBA MEDICAL COLLEGE   (India)

Author keywords

Antiviral drugs; Bird flu; Drug resistance

Indexed keywords

AMANTADINE; DNA VACCINE; INFLUENZA VACCINE; OSELTAMIVIR; RIMANTADINE; SIALIDASE INHIBITOR; VIRUS VACCINE; ZANAMIVIR;

ADENOVIRUS VECTOR; ANTIBIOTIC RESISTANCE; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; AVIAN INFLUENZA; BRONCHOSPASM; CONFUSION; COST EFFECTIVENESS ANALYSIS; COUGHING; DIABETES MELLITUS; DIARRHEA; DISEASE EXACERBATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG COST; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG FEVER; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EGG ALLERGY; EPIDEMIC; FACE EDEMA; FATIGUE; GENETIC ENGINEERING; GERIATRIC PATIENT; HEART ARRHYTHMIA; HEPATITIS; HIGH RISK PATIENT; HUMAN; IC 50; INFECTION CONTROL; INFECTION PREVENTION; INFECTION SENSITIVITY; INFLUENZA VACCINATION; INFLUENZA VIRUS A; INSOMNIA; MAXIMUM ALLOWABLE CONCENTRATION; NAUSEA; PSEUDOMEMBRANOUS COLITIS; REVIEW; SEIZURE; SURVIVAL TIME; SYNCOPE; TONGUE EDEMA; TOXIC EPIDERMAL NECROLYSIS; TREATMENT INDICATION; UNSTABLE ANGINA PECTORIS; URTICARIA; VERTIGO; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS ISOLATION; VIRUS LOAD; VIRUS PATHOGENESIS; VIRUS STRAIN; VIRUS TRANSMISSION; VOMITING;

EID: 33845270426     PISSN: 02537613     EISSN: None     Source Type: Journal    
DOI: 10.4103/0253-7613.28203     Document Type: Review

References (52)

1. Johnson NP, Mueller J. Updating the account lobal mortality of the 1918-1920 "Spanish" influenza pandemic. Bull Hist Med 2002;76:105-15.
2. Hseih YC, Wu TZ, Liu DP, Shao PL, Chang LY, Lu CY, et al. Influenza pandemics: Past, present and future. J Formos Med Assoc 2006;105:1-6.
3. Wong SS, Yuen KY. Avian influenza virus infections in humans. Chest 2006;129:156-68.
4. Sims LD, Domenech J, Benigno C, Kahn S, Kamata A, Lubroth J, et al. Origin and evolution of highly pathogenic H5N1 avian influenza in Asia. Vet Rec 2005;157:159-64.
5. Tam JS. Influenza A (H5N1) in Hong Kong: An overview. Vaccine 2002;20:77-81.
6. Shortridge KF, Peiris JS, Guan Y. The next influenza pandemic: Lessons from Hong Kong. J Appl Microbiol 2003;94:70-9.
7. Koopmans M, Wilbrink B, Conyn M, Natrop G, van der Nat H, Vennema H, et al. Transmission of H7N7 avian influenza A virus to human beings during a large outbreak in commercial poultry farms in the Netherlands. Lancet 2004;363:587-93.
8. World Health Organisation. Avian Influenza- frequently asked questions. [accessed: 2006 May 2]. Available from: http://www.who.int/csr/disease/ avian_influenza/avian_faqs/en/index.html
9. Webster RG, Guan Y, Poon L, Krauss S, Webby R, Govorkovai E, et al. The spread of the H5N1 bird flu epidemic in Asia in 2004. Arch Virol Suppl 2005;19:117-29.
10. Jameel S. The birds are coming: Are we ready? Indian J Med Res 2005;122:277-81.
11. Taubenberger JK, Morens DM. 1918 Influenza: The mother of all pandemics. Emerging Infect Dis 2006;12:15-22.
12. th century. Emerg Infect Dis 2006;12:9-14.
13. Jefferson T, Demicheli V, Rivetti D, Jones M, Di Pietrantonj C, Rivetti A. Antivirals for influenza in healthy adults: Systematic review. Lancet 2006;367:303-13.
14. Jefferson T, Demicheli V, Rivetti D, Jones M, Di Pietrantonj C, Rivetti A. Antivirals for influenza in healthy adults: Systematic review. Lancet 2006;367:303-13.
15. Oseltamivir. [accessed: 2006 May 3]. Available from: http://en.wikipedia. org/wiki/oseltamivirf
16. Li W, Escarpe PA, Eisenberg EJ, Cundy KC, Sweet C, Jakeman KJ, et al. Identification of GS 4104 as an orally bioavailable prodrug of the influenza virus neuraminidase inhibitor GS 4071. Antimicrob Agents Chemother 1998;42:647-53.
17. Mendel DB, Tai CY, Escarpe PA, Li W, Sidwell RW, Huffman JH, et al. Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS 4071 protects mice and ferrets against influenza infection. Antimicrob Agents Chemother 1998;42:640-6.
18. Leneva IA, Roberts N, Govorkova EA, Goloubeva OG, Webster RG. The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/ Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza viruses. Antiviral Res 2000;48:101-15.
19. Govorkova EA, Leneva IA, Goloubeva OG, Bush K, Webster RG. Comparison of efficacies of RWJ-270201, zanamivir and oseltamivir against H5N1, H9N2, and other avian influenza viruses. Antimicrob Agents Chemother 2001;45:2723-32.
20. Product Information: Tamiflu(R) oseltamivir phosphate capsules and for oral suspension. Nutley, NJ: Roche Pharmaceuticals; 2001.
21. Wood ND, Aitken M, Sharp S, Evison H. Tolerability and pharmacokinetics of the influenza neuraminidase inhibitor Ro 64-0802 (GS4071) following oral administration of the prodrug Ro 64-0796 (GS4104) to healthy male volunteers. Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997 Sep 27-28; Washington, DC; 1997. p. 25.
22. Beigel JH, Farrar J, Han AM, Hayden FG, Hyer R, de Jong MD, et al. Avian influenza A (H5N1) infection in humans. N Engl J Med 2005;353:1374-85.
23. Aoki F, Osterhaus A, Rimmelzwaan G, Kinnersley W, Ward P. Oral GS4104 successfully reduces duration and severity of naturally acquired influenza. Final Program and Exhibition Addendum of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy: Late breaker abstracts. 1998 Sept 22; Washington; 1998. DC. Abstr LB-5.
24. Hayden FG, Lobo M, Treanor JJ. Efficacy and tolerability of oral GS4104 for early treatment of experimental influenza in humans (abstract). 37th ICAAC Program Addendum: 1997 Sept 28; Abstr 14.
25. Oseltamivir. In: Lacy CF, Armstrong LL, Goldman M, Lance LL, editors. Lexi-Comp's Drug Information Handbook. 11th ed. Hudson, Ohio: Lexi-Comp Inc publication; 2003. p.1036-37.
26. CDC: Centers for Disease Control and Prevention. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices. MMWR 2002; 51:15-31.
27. Waghorn SL, Goa KL. Zanamivir. Drugs 1998;55:721-5.
28. Leneva IA, Goloubeva O, Fenton RJ, Tisdale M, Webster RG. Efficacy of zanamivir against avian influenza A viruses that possess genes encoding H5N1 internal proteins and are pathogenic in mammals. Antimicrob Agents Chemother 2001;45:1216-24.
29. Product Information: Relenza(R), zanamivir for inhalation. Glaxo Wellcome, Research Triangle Park, NC, 2000.
30. Peng AW, Hussey EK, Rosolowski B, Blumer JL. Pharmacokinetics and tolerability of a single inhaled dose of zanamivir in children. Curr Ther Res 2000;61:36-46.
31. Cass LM, Efthymiopoulos C, Bye A. Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers. Clin Pharmacokinet 1999;36:1-11.
32. Brady B, McAuley L, Shukla VK. Economic evaluation of zanamivir for the treatment of influenza. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA). Technology report no 13. [cited 2001, Sep 10]. Available from: http://www.ccohta.ca
33. The MIST study group. Randomized trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. Lancet 1998;353:1877-81.
34. Drugs for non-HIV viral infections. Med Lett Drugs Ther 2002;44:9-16.
35. Murphy KR, Eivindson A, Pauksens K, William, Tellier G, Watts R, et al. Efficacy and safety of inhaled zanamivir for the treatment of influenza in patients with asthma or chronic obstructive pulmonary disease. A double-blind, randomised, placebo-controlled, multicentre study. Clin Drug Invest 2000;20:337-49.
36. Williamson JC, Pegram PS. Respiratory distress associated with zanamivir. N Engl J Med 2000;342:661-2.
37. Zanamivir. In: Lacy CF, Armstrong LL, Goldman M, Lance LL, editors. Lexi-Comp's Drug Information Handbook. 11th ed. Hudson, Ohio: Lexi-Comp Inc publication; 2003. p.1463-64.
38. Webster A, Boyce M, Edmundson S, Miller I. Coadministration of orally inhaled zanamivir with inactivated trivalent influenza vaccine does not adversely affect the production of antihaemagglutinin antibodies in the serum of healthy volunteers. Clin Pharmacokinet 1999;36:51-8.
39. Mauskopf JA, Cates SC, Griffin AD, Neighbors DM, Lamb SC, Rutherford C. Cost effectiveness of zanamivir for the treatment of influenza in a high risk population in Australia. Pharmacoeconomics 2000;17:611-20.
40. Moscona A. Neuraminidase inhibitors for influenza. N Eng J Med 2005;353:1363-73.
41. The Writing Committee of the World Health Organization (WHO) Consultation on Human Influenza A/H5. Avian influenza A (H5N1) infection in humans. N Eng J Med 2005;353:1374-85.
42. Hayden FG, Lobo M, Hussey EK. Efficacy of intranasal GG167 in experimental human influenza A and B virus infection. In: Brown LE, Hampson AW, Webster RG, editors. Options for the control of influenza III: Proceedings for the Third International Conference for the Control of Influenza, 1996 May 4-9.718-25.
43. Varghese JN, Smith PW, Sollis SL, Blick TJ, Sahasrabudhe A, McKimm-Breschkin JL, et al. Drug design against a shifting target: A structural basis for resistance to inhibitors in a variant of influenza virus neuraminidase. Structure 1998;6:735-46.
44. Moscona A. Oseltamivir Resistance - disabling our influenza defenses. N Eng J Med 2005;353:2633-6.
45. Palese P. Making Better Influenza Virus Vaccines. Emerg Infect Dis 2006;12:61-5.
46. Influenza vaccine 2005-2006. The Medical Letter 2005;47:85.
47. Tables for Influenza: January 2006. [accessed: 2006 May 2]. Medscape Infectious Diseases 2006;8(1) obtained from www.medscape.com.
48. Lee CW, Suarez DL. Avian influenza virus: Prospects for prevention and control by vaccination. Anim Health Res Rev 2005;1:1-15.
49. Tollis M, Di Trani L. Recent developments in avian influenza research, epidemiology and immunoprophylaxis. Vet J 2002;164:202-15.
50. Lee CW, Seene DA, Suarez DL. Generation of reassortant influenza vaccines by reverse genetics that allows utilization of a DIVA (Differentiating Infected from Vaccinated Animals) Strategy for the control of avian influenza. Vaccine 2004;22:3175-81.
51. Neumann G, Hatta M, Kawaoka Y. Reverse genetics for the control of avian influenza. Avian Dis 203;47:882-7.
52. Cass LM, Brown J, Pickford M, Fayinka S, Newman SP, Johansson CJ, et al. Pharmacoscintigraphic evaluation of lung deposition of inhaled zanamivir in healthy volunteers. Clin Pharmacokinet 1999;36:21-31.